C4X Discovery Holdings PLC Collaboration with e-Therapeutics
May 01 2018 - 1:00AM
RNS Non-Regulatory
TIDMC4XD
C4X Discovery Holdings PLC
01 May 2018
C4X Discovery Holdings plc
("C4XD", "C4X Discovery" or the "Company")
Collaboration with e-Therapeutics to identify novel mechanisms
for the treatment of Parkinson's Disease
1 May 2018 - C4X Discovery Holdings plc (AIM: C4XD), a
pioneering drug discovery company, announces that it has entered
into a joint research collaboration with e-Therapeutics plc (AIM:
ETX) to identify novel mechanistic insights into Parkinson's
Disease (PD). The collaboration utilises both companies' drug
discovery technologies, in particular C4XD's Taxonomy3(R) novel
target identification platform and ETX's Network-driven Drug
Discovery (NDD) capabilities. Teams from both companies will use
the outputs from C4XD's Taxonomy3(R) genetic analysis of PD and
apply an NDD approach to identify novel intervention strategies
which it is expected will lead to new approaches for the treatment
of PD.
C4XD's proprietary target discovery technology Taxonomy3(R) has
identified 180 novel disease associated genes in Parkinson's
Disease (PD) in addition to the identification of discrete patient
sub-groups that could potentially provide an opportunity in
stratified medicine. The discovery of these new genetic
associations further confirms the power of Taxonomy3(R) to generate
novel genetic insights into diseases with high unmet medical need.
To put these findings into context, at the start of 2017 only 40 PD
associated genes were known in the scientific literature, and last
September, Genentech and 23andme published the results of their
collaboration in the scientific journal Nature Genetics (Nature
Genetics 49, 1511-1516, 2017), which identified a further 17 novel
genetic variants representing 32 new PD associated genes.
The combination of C4XD's proprietary novel disease associated
genes with known PD literature genes provides a unique and rich
dataset to apply to ETX's NDD platform, harnessing the latest
mathematical and data analysis techniques to augment and
interrogate complex biological information. This approach is
expected to reveal further unique disease insights that may lead to
additional drug discovery programmes beyond those identified by
C4XD to date.
Terms of the agreement are undisclosed.
Dr Craig Fox, CSO of C4X Discovery, said: "This collaboration
not only demonstrates the potential of C4XD's drug discovery
technologies but also highlights our desire to maximise the value
from our novel genetic analysis by accessing complementary and
synergistic proprietary technologies. This strategy will most
effectively support our pursuit of licensable pre-clinical drug
assets, such as the Orexin-1 receptor antagonist recently licensed
to Indivior for up to $294m. We look forward to working with
e-Therapeutics and to a successful outcome."
--ENDS-
For further information, please contact:
C4X Discovery Holdings plc
Clive Dix, Chief Executive Officer 07801 865 803
Panmure Gordon (UK) Limited (NOMAD and Broker) 020 7886 2500
Freddy Crossley, Emma Earl (Corporate Finance)
Consilium Strategic Communications
Mary-Jane Elliott, Chris Gardner, Matthew Neal 0203 709 5700
About C4X Discovery
C4X Discovery aims to become the world's most productive drug
discovery engine by exploiting cutting edge technologies to design
and create best-in-class small-molecule candidates targeting a
range of high value therapeutic areas. The company's goal is to
drive returns through early-stage revenue-generating deals with the
pharmaceutical industry.
C4X Discovery has a state-of-the-art suite of proprietary
technologies across the drug discovery process. The company's
innovative DNA-based target identification platform (Taxonomy3(R))
utilises human genetic datasets to identify novel patient-specific
targets leading to greater discovery productivity and increased
probability of clinical success. This is complemented by C4XD's
novel drug design platform which comprises two innovative chemistry
technologies, Conformetrix and Molplex, that combine 4D molecular
shape analyses (based on experimental data) with best-in-class
computational chemistry. This provides new and unprecedented
insight into the behaviour of drug molecules, enabling the
production of potent selective compounds faster and more cost
effectively than the industry standard.
C4X Discovery is advancing its in-house pipeline in
inflammation, neurodegeneration, immuno-oncology, addiction, and
diabetes with a number of new drug candidates identified and
further progress made towards the pre-clinical licensing
discussions. In selecting new targets C4X Discovery will focus on
the high-value disease areas and will continue to maximise value
from opportunistic areas, for example, immuno-oncology, addiction,
and diabetes.
The Company was founded as a spin-out from the University of
Manchester. It has a highly experienced management team and Board
who have delivered significant value creation within the healthcare
sector historically and have enabled C4XD to reach multiple value
inflexion points since IPO. For additional information please go
to: www.c4xdiscovery.com
About e-Therapeutics plc
e-Therapeutics plc is an Oxford-based company with a unique and
powerful computer-based drug discovery platform and specialised
approach to network biology.
Its novel methodology and discovery engine allow the Company to
discover new and better drugs in a more efficient and effective
way.
For more information about e-Therapeutics, please visit
www.etherapeutics.co.uk
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRADBGDSBBXBGIG
(END) Dow Jones Newswires
May 01, 2018 02:00 ET (06:00 GMT)
C4x Discovery (LSE:C4XD)
Historical Stock Chart
From Apr 2024 to May 2024
C4x Discovery (LSE:C4XD)
Historical Stock Chart
From May 2023 to May 2024